001     310011
005     20260223120902.0
024 7 _ |a 10.1002/path.70039
|2 doi
024 7 _ |a pmid:41716034
|2 pmid
024 7 _ |a 0368-3494
|2 ISSN
024 7 _ |a 0022-3417
|2 ISSN
024 7 _ |a 1096-9896
|2 ISSN
024 7 _ |a 1555-2039
|2 ISSN
037 _ _ |a DKFZ-2026-00424
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Reitsam, Nic G
|0 0000-0002-0070-3158
|b 0
245 _ _ |a Deep learning-based H&E-derived risk scores in colorectal cancer: associations with tumour morphology, biology, and predicted drug response.
260 _ _ |a Bognor Regis [u.a.]
|c 2026
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1771842278_3895551
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a epub
520 _ _ |a Over recent years, several deep learning (DL) models have been presented to predict colorectal cancer (CRC) patient survival directly from haematoxylin and eosin (H&E)-stained routine whole-slide images (WSIs). Unlike traditional studies that rely on manually defined histopathological features, weakly supervised DL allows training directly on clinical endpoints without prior specification of the model's focus. This offers a unique opportunity to study the tissue morphology underlying these predictions, improving our understanding of disease biology. Here, we present a comprehensive analysis of the clinicopathological features, tumour morphology and biology, as well as gene expression-based predicted drug response of over 4,000 CRC patients derived from four different international cohorts with available H&E-inferred DL-based risk scores (low- versus high-risk as well as absolute risk scores). The results from our study suggest that conventional clinicopathological risk factors, such as grade of differentiation, presence of lymph node metastasis, tumour budding, and percentage of tumour necrosis, are positively associated with DL-based risk scores. Moreover, CRCs with direct tumour-adipocyte interactions are enriched in the DL-based high-risk group. Through detailed morphologic review, we provide comprehensive evidence that direct tumour-adipocyte interaction, a high degree of tumour budding, and poorly differentiated morphology are linked to high DL-based risk scores. Transcriptomic and genetic subgroups show only limited association with H&E-derived DL-based risk scores. Moreover, we present data suggesting that DL-based low- versus high-risk CRCs may be characterised by differential drug sensitivity. Our study highlights that DL-based risk scores derived from H&E WSIs not only align with established clinicopathological features but also highlight morphological features, such as tumour-adipocyte interaction, that are not routinely captured by established clinicopathological scoring systems. Moreover, DL-based risk groups may be associated with a differential treatment response, underlining their potential to guide patient stratification in routine clinical practice. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a biomarker
|2 Other
650 _ 7 |a colorectal cancer
|2 Other
650 _ 7 |a computational pathology
|2 Other
650 _ 7 |a deep learning
|2 Other
650 _ 7 |a drug response
|2 Other
650 _ 7 |a gene expression
|2 Other
650 _ 7 |a histopathology
|2 Other
650 _ 7 |a pathology
|2 Other
650 _ 7 |a whole‐slide image
|2 Other
700 1 _ |a Jiang, Xiaofeng
|b 1
700 1 _ |a Liang, Junhao
|b 2
700 1 _ |a Grosser, Bianca
|b 3
700 1 _ |a Grozdanov, Veselin
|0 0000-0002-0825-7383
|b 4
700 1 _ |a Loeffler, Chiara Ml
|b 5
700 1 _ |a Gustav, Marco
|0 0009-0009-3598-5720
|b 6
700 1 _ |a Lenz, Tim
|0 0000-0002-9034-2535
|b 7
700 1 _ |a Muti, Hannah S
|b 8
700 1 _ |a Carrero, Zunamys I
|b 9
700 1 _ |a West, Nicholas P
|0 0000-0002-0346-6709
|b 10
700 1 _ |a Quirke, Philip
|0 0000-0002-3597-5444
|b 11
700 1 _ |a Foersch, Sebastian
|b 12
700 1 _ |a Jesinghaus, Moritz
|b 13
700 1 _ |a Müller, Wolfram
|b 14
700 1 _ |a Yuan, Tanwei
|0 P:(DE-He78)b9e439a1aa1244925f92d547c0919349
|b 15
|u dkfz
700 1 _ |a Hoffmeister, Michael
|0 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f
|b 16
|u dkfz
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 17
|u dkfz
700 1 _ |a Jonnagaddala, Jitendra
|b 18
700 1 _ |a Hawkins, Nicholas J
|b 19
700 1 _ |a Ward, Robyn L
|b 20
700 1 _ |a Grabsch, Heike I
|0 0000-0001-9520-6228
|b 21
700 1 _ |a Märkl, Bruno
|b 22
700 1 _ |a Kather, Jakob N
|b 23
773 _ _ |a 10.1002/path.70039
|g p. path.70039
|0 PERI:(DE-600)1475280-3
|p nn
|t The journal of pathology
|v nn
|y 2026
|x 0368-3494
909 C O |o oai:inrepo02.dkfz.de:310011
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)b9e439a1aa1244925f92d547c0919349
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 17
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2026
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2025-11-12
|w ger
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-11-12
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J PATHOL : 2022
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-12
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-11-12
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J PATHOL : 2022
|d 2025-11-12
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie der Krebsfrüherkennung
|x 0
920 1 _ |0 I:(DE-He78)M320-20160331
|k M320
|l Koordinierungsstelle der Cancer Prevention GS
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)M320-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21